P. Albertsson, B. Lennernas, and K. Norrby, On metronomic chemotherapy: Modulation of angiogenesis mediated by VEGE-A, Acta Oncologica, vol.6, issue.2, pp.144-155, 2006.
DOI : 10.1093/carcin/21.3.505

M. Arai, A. Yoguchi, T. Takizawa, T. Yokoyama, T. Kanda et al., Mechanism of Doxorubicin-Induced Inhibition of Sarcoplasmic Reticulum Ca2+-ATPase Gene Transcription, Circulation Research, vol.86, issue.1, pp.8-14, 2000.
DOI : 10.1161/01.RES.86.1.8

R. Bennink, M. Van-den-hoff, F. Van-hemert, K. De-bruin, A. Spijkerboer et al., Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats, J Nucl Med, vol.45, pp.842-848, 2004.

J. Berthiaume and K. Wallace, Persistent Alterations to the Gene Expression Profile of the Heart Subsequent to Chronic Doxorubicin Treatment, Cardiovascular Toxicology, vol.281, issue.3, pp.178-191, 2007.
DOI : 10.1007/s12012-007-0026-0

D. Campbell, J. Stamler, and H. Strauss, Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols, The Journal of General Physiology, vol.108, issue.4, pp.277-293, 1996.
DOI : 10.1085/jgp.108.4.277

P. Carmeliet and R. Jain, Angiogenesis in cancer and other diseases, Nature, vol.407, issue.6801, pp.249-257, 2000.
DOI : 10.1038/35025220

E. De-beer, A. Bottone, J. Van-der-velden, and E. Voest, Doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment, 2000.

S. Delemasure, P. Sicard, B. Lauzier, D. Moreau, C. Vergely et al., Acute Administration of Epirubicin Induces Myocardial Depression in Isolated Rat Heart and Production of Radical Species Evaluated by Electron Spin Resonance Spectroscopy, Journal of Cardiovascular Pharmacology, vol.50, issue.6, pp.647-653, 2007.
DOI : 10.1097/FJC.0b013e31815571f7

C. Vergely, General oxidative stress during doxorubicin-induced cardiotoxicity in rats, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00828304

S. Ghibu, B. Lauzier, S. Delemasure, S. Amoureux, P. Sicard et al., Antioxidant properties of alpha-lipoic acid: effects on red blood membrane permeability and adaptation of isolated rat heart to reversible ischemia, Molecular and Cellular Biochemistry, vol.169, issue.1-2, pp.141-148, 2009.
DOI : 10.1007/s11010-008-9916-0

A. Giantris, L. Abdurrahman, A. Hinkle, B. Asselin, and S. Lipshultz, Anthracycline-induced cardiotoxicity in children and young adults, Critical Reviews in Oncology/Hematology, vol.27, issue.1, pp.53-68, 1998.
DOI : 10.1016/S1040-8428(97)10007-5

J. Goetze, L. Friis-hansen, J. Rehfeld, B. Nilsson, and J. Svendsen, Atrial secretion of B-type natriuretic peptide, European Heart Journal, vol.27, issue.14, pp.1648-1650, 2006.
DOI : 10.1093/eurheartj/ehl109

J. Goldhaber, Free radicals enhance Na+/Ca2+ exchange in ventricular myocytes, Am J Physiol, vol.271, pp.823-833, 1996.

G. Hasenfuss, Alterations of calcium-regulatory proteins in heart failure, Cardiovascular Research, vol.37, issue.2, pp.279-289, 1998.
DOI : 10.1016/S0008-6363(97)00277-0

S. Izumo, B. Nadal-ginard, and V. Mahdavi, Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload., Proceedings of the National Academy of Sciences, vol.85, issue.2, pp.339-343, 1988.
DOI : 10.1073/pnas.85.2.339

E. Kranias and D. Bers, Calcium and Cardiomyopathies, Subcell Biochem, vol.45, pp.523-537, 2007.
DOI : 10.1007/978-1-4020-6191-2_20

L. Kremer, E. Van-dalen, M. Offringa, J. Ottenkamp, and P. Voute, Anthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study, Journal of Clinical Oncology, vol.19, issue.1, pp.191-196, 2001.
DOI : 10.1200/JCO.2001.19.1.191

C. Maggi, S. Manzini, and G. Minotti, Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity, Br J Pharmacol, vol.139, pp.641-651, 2003.

A. Sanbe, J. James, V. Tuzcu, S. Nas, L. Martin et al., Transgenic Rabbit Model for Human Troponin I-Based Hypertrophic Cardiomyopathy, Circulation, vol.111, issue.18, pp.2330-2338, 2005.
DOI : 10.1161/01.CIR.0000164234.24957.75

R. Scully and S. Lipshultz, Anthracycline cardiotoxicity in long-term survivors of childhood cancer, Cardiovascular Toxicology, vol.25, issue.2, pp.122-128, 2007.
DOI : 10.1007/s12012-007-0006-4

A. Swerdlow, C. Higgins, P. Smith, D. Cunningham, B. Hancock et al., Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study, JNCI Journal of the National Cancer Institute, vol.99, issue.3, pp.206-214, 2007.
DOI : 10.1093/jnci/djk029

G. Takemura and H. Fujiwara, Doxorubicin-Induced Cardiomyopathy, Progress in Cardiovascular Diseases, vol.49, issue.5, pp.330-352, 2007.
DOI : 10.1016/j.pcad.2006.10.002

J. Alpert, K. Thygesen, E. Antman, and J. Bassand, Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction, J Am Coll Cardiol, vol.36, pp.959-969, 2000.

M. Ando, T. Yokozawa, J. Sawada, Y. Takaue, K. Togitani et al., Cardiac conduction abnormalities in patients with breast cancer undergoing high-dose chemotherapy and stem cell transplantation, Bone Marrow Transplantation, vol.25, issue.2, pp.185-189, 2000.
DOI : 10.1038/sj.bmt.1702106

M. Aplin, T. Engstrom, N. Vejlstrup, P. Clemmensen, C. Torp-pedersen et al., Prognostic importance of complete atrioventricular block complicating acute myocardial infarction, The American Journal of Cardiology, vol.92, issue.7, pp.853-856, 2003.
DOI : 10.1016/S0002-9149(03)00900-7

J. Blom, J. Vanderschoot, M. Oostindier, S. Osanto, F. Van-der-meer et al., Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study, Journal of Thrombosis and Haemostasis, vol.18, issue.3, pp.529-535, 2006.
DOI : 10.1056/NEJMoa025313

K. Bouillon, N. Haddy, S. Delaloge, J. Garbay, J. Garsi et al., Long-Term Cardiovascular Mortality After Radiotherapy for Breast Cancer, Journal of the American College of Cardiology, vol.57, issue.4, pp.445-452
DOI : 10.1016/j.jacc.2010.08.638

A. Brusca, F. Orzan, and M. Figliomeni, [Cardiopathy due to therapeutic irradiation of the thorax. The diagnostic criteria], Cardiologia, vol.38, pp.163-172, 1993.

D. Busseuil, C. B. Rioufol, G. Korandji, C. Zeller, M. Maingon et al., Combining Sirolimus-eluting Stents and External Irradiation in Cholesterol-fed Rabbits Increased Incomplete Stent Apposition and Decreased Re-endothelialization, Journal of Cardiovascular Pharmacology, vol.53, issue.4, pp.318-324, 2009.
DOI : 10.1097/FJC.0b013e31819f1bca

G. Caine, G. Lip, P. Stonelake, P. Ryan, and A. Blann, Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma, Thrombosis and Haemostasis, vol.92, pp.185-190, 2004.
DOI : 10.1160/TH03-11-0679

H. Chew, T. Wun, D. Harvey, H. Zhou, and R. White, Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common Cancers, Archives of Internal Medicine, vol.166, issue.4, pp.458-464, 2006.
DOI : 10.1001/archinte.166.4.458

M. Crandall, D. Bradley, D. Packer, and S. Asirvatham, Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies, Mayo Clinic Proceedings, vol.84, issue.7, pp.643-662, 2009.
DOI : 10.1016/S0025-6196(11)60754-4

T. Dabakuyo, F. Bonnetain, P. Roignot, M. Poillot, G. Chaplain et al., Population-based study of breast cancer survival in Cote d'Or (France): prognostic factors and relative survival, Annals of Oncology, vol.19, issue.2, pp.276-283, 2008.
DOI : 10.1093/annonc/mdm491

I. Dogan, O. Sezen, B. Sonmez, A. Zengin, E. Yenilmez et al., Myocardial perfusion alterations observed months after radiotherapy are related to the cellular damage, Nuklearmedizin, vol.49, issue.6, pp.209-215, 2010.
DOI : 10.3413/nukmed-0315-10-05

J. Doyle, A. Neugut, J. Jacobson, V. Grann, and D. Hershman, Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study, Journal of Clinical Oncology, vol.23, issue.34, pp.8597-8605, 2005.
DOI : 10.1200/JCO.2005.02.5841

C. Dubois, C. Pappas, A. Belmans, K. Erven, T. Adriaenssens et al., Clinical outcome of coronary stenting after thoracic radiotherapy: a case-control study, Heart, vol.96, issue.9, pp.678-682
DOI : 10.1136/hrt.2009.183129

R. Erichsen, C. Christiansen, F. Mehnert, N. Weiss, J. Baron et al., Colorectal cancer and risk of atrial fibrillation and flutter: a population-based casecontrol study) A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment, Intern Emerg Med Ewer MS Cancer Falanga A Cancer Invest, vol.18, issue.27, pp.1813-1826105, 2009.

K. Fox, O. Dabbous, R. Goldberg, K. Pieper, K. Eagle et al., Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) The cardiac contractile function and hemodynamic control in rats after chronic adriamycin treatment, BMJ Can J Physiol Pharmacol, vol.333, issue.68, pp.1091-21211, 1990.

A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu et al., Cancer Statistics, 2006, Cancer statistics, pp.106-130, 2006.
DOI : 10.3322/canjclin.56.2.106

T. Jeon, J. Lee, J. Ha, W. Yang, and S. Cho, Evaluation of cardiac adrenergic neuronal damage in rats with doxorubicin-induced cardiomyopathy using iodine-131 MIBG autoradiography and PGP 9.5 immunohistochemistry, European Journal of Nuclear Medicine and Molecular Imaging, vol.27, issue.6, pp.686-693, 2000.
DOI : 10.1007/s002590050563

L. Jones, M. Haykowsky, J. Swartz, P. Douglas, and J. Mackey, Early Breast Cancer Therapy and Cardiovascular Injury, Journal of the American College of Cardiology, vol.50, issue.15, pp.1435-1441, 2007.
DOI : 10.1016/j.jacc.2007.06.037

A. Leenhardt, P. Maison-blanche, I. Denjoy, B. Cauchemez, J. Joubert et al., Koracevic GP Cancer is an Insufficiently Recognized Risk Factor for Atrial Fibrillation, Mechanism of spontaneous occurrence of tachycardia]. Arch Mal Coeur Vaiss 92 Spec, pp.17-22, 1999.

J. Lopez-sendon, O. Dabbous, E. Lopez-de-sa, M. Stiles, J. Gore et al., In-Hospital Outcomes Associated With Fibrinolytic and Thienopyridine Use in Patients With ST-Segment Elevation Acute Myocardial Infarction. The Global Registry of Acute Coronary Events, Revista Espa??ola de Cardiolog??a (English Edition), vol.62, issue.5, pp.501-509, 2009.
DOI : 10.1016/S1885-5857(09)71832-8

I. Lorincz, Z. Szabo, J. Simko, E. Szantho, K. Barta et al., Atrial fibrillation and the autonomous nervous system, Atrial fibrillation and the autonomous nervous system], pp.2019-2028, 2008.
DOI : 10.1556/OH.2008.28466

L. Marks, X. Yu, R. Prosnitz, S. Zhou, P. Hardenbergh et al., The incidence and functional consequences of RT-associated cardiac perfusion defects, International Journal of Radiation Oncology*Biology*Physics, vol.63, issue.1, pp.214-223, 2005.
DOI : 10.1016/j.ijrobp.2005.01.029

N. Meshkat, E. Austin, R. Moineddin, H. Hatamabadi, B. Hassani et al., Troponin utilization in patients presenting with atrial fibrillation/flutter to the emergency department: retrospective chart review, International Journal of Emergency Medicine, vol.4, issue.1, p.25, 2011.
DOI : 10.1056/NEJMoa0903515

J. Monsuez, J. Charniot, and N. Vignat, Cardiac side-effects of cancer chemotherapy, International Journal of Cardiology, vol.144, issue.1, pp.3-15
DOI : 10.1016/j.ijcard.2010.03.003

G. Nilsson, L. Holmberg, H. Garmo, A. Terent, and C. Blomqvist, Increased incidence of stroke in women with breast cancer, European Journal of Cancer, vol.41, issue.3, pp.423-429, 2005.
DOI : 10.1016/j.ejca.2004.11.013

G. Nilsson, L. Holmberg, H. Garmo, A. Terent, and C. Blomqvist, Radiation to supraclavicular and internal mammary lymph nodes in breast cancer increases the risk of stroke, British Journal of Cancer, vol.67, issue.5, pp.811-816, 2009.
DOI : 10.1002/cncr.21943

H. Otten, J. Mathijssen, H. Ten-cate, M. Soesan, M. Inghels et al., Symptomatic Venous Thromboembolism in Cancer Patients Treated With Chemotherapy, Archives of Internal Medicine, vol.164, issue.2, pp.190-194, 2004.
DOI : 10.1001/archinte.164.2.190

D. Patt, J. Goodwin, Y. Kuo, J. Freeman, D. Zhang et al., Cardiac Morbidity of Adjuvant Radiotherapy for Breast Cancer, Journal of Clinical Oncology, vol.23, issue.30, pp.7475-7482, 2005.
DOI : 10.1200/JCO.2005.13.755

E. Senkus-konefka and J. Jassem, Cardiovascular effects of breast cancer radiotherapy, Cancer Treatment Reviews, vol.33, issue.6, pp.578-593, 2007.
DOI : 10.1016/j.ctrv.2007.07.011

J. Silva, H. Oliveira, M. Camacho, J. Pais, and A. Leitao-marques, Carotid stenting for radiation-induced carotid artery stenosis: a challenge?, Rev Port Cardiol, vol.30, pp.73-80, 2011.

H. Sorensen, L. Mellemkjaer, J. Olsen, and J. Baron, Prognosis of Cancers Associated with Venous Thromboembolism, New England Journal of Medicine, vol.343, issue.25, pp.1846-1850, 2000.
DOI : 10.1056/NEJM200012213432504

O. Stefan, N. Vera, B. Otto, L. Heinz, and W. G. , Stroke in cancer patients: a risk factor analysis, Journal of Neuro-Oncology, vol.6, issue.2, pp.221-226, 2009.
DOI : 10.1007/s11060-009-9818-3

P. Stein, A. Beemath, F. Meyers, E. Skaf, J. Sanchez et al., Incidence of Venous Thromboembolism in Patients Hospitalized with Cancer, The American Journal of Medicine, vol.119, issue.1, pp.60-68, 2006.
DOI : 10.1016/j.amjmed.2005.06.058

F. Stewart, S. Hoving, and N. Russell, Vascular Damage as an Underlying Mechanism of Cardiac and Cerebral Toxicity in Irradiated Cancer Patients, Radiation Research, vol.174, issue.6b, pp.865-869, 2010.
DOI : 10.1667/RR1862.1

D. Tzivoni, E. Ratzkowski, S. Biran, J. Brook, and S. Stern, Complete Heart Block Following Therapeutic Irradiation of the Left Side of the Chest, Chest, vol.71, issue.2, pp.231-234, 1977.
DOI : 10.1378/chest.71.2.231

P. Velagapudi, M. Turagam, and A. Kocheril, Atrial Fibrillation in Cancer Patients, Southern Medical Journal, vol.104, issue.9, pp.667-668
DOI : 10.1097/SMJ.0b013e3182299e6c

D. Wheeler, T. Liew, and A. Bailey, Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel, Anaesthesia, vol.69, issue.2, pp.186-189, 2007.
DOI : 10.1016/S0046-8177(96)90447-5

E. Yeh, Cardiotoxicity Induced by Chemotherapy and Antibody Therapy, Annual Review of Medicine, vol.57, issue.1, pp.485-498, 2006.
DOI : 10.1146/annurev.med.57.121304.131240

T. Yeo, S. Teo, and W. Soo, Poh KK Variations of atrioventricular block, Singapore Med J, vol.52, pp.330-334

M. Zeller, P. Steg, J. Ravisy, L. Lorgis, Y. Laurent et al., Relation Between Body Mass Index, Waist Circumference, and Death After Acute Myocardial Infarction, Circulation, vol.118, issue.5, pp.482-490, 2008.
DOI : 10.1161/CIRCULATIONAHA.107.753483

E. G. Dib, M. R. Kidd, and D. C. Saltman, Case reports and the fight against cancer, Journal of Medical Case Reports, vol.357, issue.3, p.39, 2008.
DOI : 10.1056/NEJMoa071407

M. Tubiana, G??n??ralit??s sur la canc??rogen??se, Comptes Rendus Biologies, vol.331, issue.2, pp.114-139, 2008.
DOI : 10.1016/j.crvi.2007.03.003

V. T. Chan and J. O. Mcgee, Cellular oncogenes in neoplasia., Journal of Clinical Pathology, vol.40, issue.9, pp.1055-63, 1987.
DOI : 10.1136/jcp.40.9.1055

R. T. Javier and J. S. Butel, The History of Tumor Virology, Cancer Research, vol.68, issue.19, pp.7693-706, 2008.
DOI : 10.1158/0008-5472.CAN-08-3301

R. Sarid and S. J. Gao, Viruses and human cancer: From detection to causality, Cancer Letters, vol.305, issue.2, pp.218-245, 2011.
DOI : 10.1016/j.canlet.2010.09.011

J. Davidson-moncada, F. N. Papavasiliou, and W. Tam, MicroRNAs of the immune system, Annals of the New York Academy of Sciences, vol.10, issue.1, pp.183-94, 1183.
DOI : 10.1111/j.1749-6632.2009.05121.x

M. Vaish, Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications, Molecular Cancer, vol.6, issue.1, p.26, 2007.
DOI : 10.1186/1476-4598-6-26

R. Monier, Aspects fondamentaux??: m??canismes de canc??rogen??se et relation dose???effet, Comptes Rendus de l'Acad??mie des Sciences - Series III - Sciences de la Vie, vol.323, issue.7, pp.603-613, 2000.
DOI : 10.1016/S0764-4469(00)00161-X

C. Du, Y. Wang, W. B. , and D. L. Longo, The immunoregulatory mechanisms of carcinoma for its survival and development Aging and cancer: issues of basic and clinical science, J Exp Clin Cancer Res. J Natl Cancer Inst, vol.30, issue.20, pp.89-1489, 1997.

I. B. Weinstein and P. A. Oliveira, The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatment--twentyseventh G.H.A. Clowes memorial award lecture, Cancer Res Chemical carcinogenesis. An Acad Bras Cienc, vol.12, issue.154, pp.48-4135, 1988.

S. Paul and E. Regulier, [Molecular basis of oncogenesis], Ann Biol Clin, vol.59, issue.4, pp.393-402, 2001.

B. Delaval and D. Birnbaum, A cell cycle hypothesis of cooperative oncogenesis (Review), International Journal of Oncology, vol.30, issue.5, pp.1051-1059, 2007.
DOI : 10.3892/ijo.30.5.1051

P. Morice, [Conservative surgical in oncology], Bull Cancer, vol.89, issue.12, pp.1001-1003, 2002.

D. Elias, [Rational of oncological surgery in multimodality treatment of cancers], Bull Cancer, issue.8, pp.93-775, 2006.

J. M. Classe, Chirurgie des cancers invasifs du sein (?? l???exception de la reconstruction mammaire), Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.39, issue.8, pp.43-62, 2010.
DOI : 10.1016/j.jgyn.2010.10.002

K. M. Schmeler, M. Frumovitz, and P. T. Ramirez, Conservative management of early stage cervical cancer: Is there a role for less radical surgery?, Gynecologic Oncology, vol.120, issue.3, pp.321-326, 2011.
DOI : 10.1016/j.ygyno.2010.12.352

S. P. Leong, Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients Diagnosis and management of metastatic spine disease, J Surg Oncol J Neurosurg Spine, vol.103, issue.131, pp.94-108, 2010.

E. Itshayek, Timing of surgery and radiotherapy in the management of metastatic spine disease: a systematic review, Int J Oncol, vol.36, issue.3, pp.533-577, 2010.

J. A. Paice and B. Ferrell, The management of cancer pain, CA: A Cancer Journal for Clinicians, vol.12, issue.1 suppl, pp.61-157, 2011.
DOI : 10.3322/caac.20112

P. Ponsot and P. Hammel, [Malignant duodenal stenoses: can endoscopic or radiological insertion of metal stent replace surgical derivation?] Endocrine therapy of metastatic breast cancer, Gastroenterol Clin Biol Keio J Med, vol.2489, issue.263, pp.705-712, 1987.

S. J. Kronowitz, H. M. Kuerer-winters, Z. E. , J. R. Benson, and A. L. Pusic, Advances and surgical decision-making for breast reconstruction. Cancer A systematic review of the clinical evidence to guide treatment recommendations in breast reconstruction based on patient-reported outcome measures and health-related quality of life The history of radiation use in medicine, 3S-5S. 30. Cosset, J.M., [Side effects of ionizing radiation on healthy tissues and organs at risk]. Cancer Radiother, pp.893-907, 2006.

M. Sadeghi, M. Enferadi, and A. Shirazi, External and internal radiation therapy: Past and future directions, Journal of Cancer Research and Therapeutics, vol.6, issue.3, pp.239-287, 2010.
DOI : 10.4103/0973-1482.73324

N. Nicolaou, Radiation therapy treatment planning and delivery, Semin Oncol Nurs, vol.15, issue.4, pp.260-269, 1999.

E. Briot, Optimisation en curieth??rapie, Cancer/Radioth??rapie, vol.7, issue.2, pp.147-52, 2003.
DOI : 10.1016/S1278-3218(02)00281-0

C. Hennequin, L. Quero, V. Favaudon, and K. M. , [Determinants and predictive factors of tumour radiosensitivity]. Cancer Radiother New insights on cell death from radiation exposure, Lancet Oncol, vol.12, issue.1 67, pp.3-13, 2005.

P. P. Kumar, F. Bahrassa, and M. C. Espinoza, The role of radiotherapy in management of metastatic bone disease, J Natl Med Assoc, issue.12, pp.70-909, 1978.

S. Bolle, C. Louis, and P. A. , Coucke, [Innovative technologies in radiation oncology] The role of radiation therapy in the control of locoregional and metastatic cancer, Rev Med Liege J Surg Oncol, vol.62, issue.1036, pp.5-6, 2007.

T. S. Hong, Intensity-modulated radiation therapy: emerging cancer treatment technology, British Journal of Cancer, vol.8, issue.10, pp.92-1819, 2005.
DOI : 10.1016/S0360-3016(98)00091-1

G. Kantor, [French national evaluation for helicoidal tomotherapy: description of indications, dose constraints and set-up margins]. Cancer Radiother, pp.11-17, 2007.

P. Y. Bondiau, Radioth??rapie st??r??otaxique robotis??e par??CyberKnife??: aspects techniques et??indications, Cancer/Radioth??rapie, vol.11, issue.6-7, pp.338-382, 2007.
DOI : 10.1016/j.canrad.2007.09.146

J. M. Hannoun-levi, [Robotic radiotherapy for prostate cancer with CyberKnife]. Cancer Radiother, pp.476-82, 2007.

A. Joubert, Biologie des radiations??: avanc??es majeures et perspectives pour la radioth??rapie, Cancer/Radioth??rapie, vol.15, issue.5, pp.348-54, 2011.
DOI : 10.1016/j.canrad.2011.05.001

A. C. Begg, F. A. Stewart, and C. Vens, Strategies to improve radiotherapy with targeted drugs, Nature Reviews Cancer, vol.77, issue.4, pp.239-53, 2011.
DOI : 10.1038/nrc3007

J. F. Chatal, Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors, Journal of Cancer Research and Therapeutics, vol.5, issue.9, pp.36-40, 2009.
DOI : 10.4103/0973-1482.55139

G. K. Dy and A. A. Adjei, Systemic cancer therapy: Evolution over the last 60 years, Cancer, vol.109, issue.18S, pp.1857-87, 2008.
DOI : 10.1002/cncr.23651

C. M. Galmarini, J. R. Mackey, and C. Dumontet, Nucleoside analogues and nucleobases in cancer treatment, The Lancet Oncology, vol.3, issue.7, pp.415-439, 2002.
DOI : 10.1016/S1470-2045(02)00788-X

B. I. Schweitzer, A. P. Dicker, and J. R. Bertino, Dihydrofolate reductase as a therapeutic target, FASEB J, issue.48, pp.2441-52, 1990.

C. H. Takimoto, New Antifolates: Pharmacology and Clinical Applications, Oncologist, vol.1, issue.1 2, pp.68-81, 1996.

N. Hagner and M. Joerger, Cancer chemotherapy: targeting folic acid synthesis, Cancer Manag Res, vol.2, pp.293-301

Z. H. Siddik, Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncogene, vol.22, issue.47, pp.7265-79, 2003.
DOI : 10.1038/sj.onc.1206933

J. Dancey and E. A. Eisenhauer, Current perspectives on camptothecins in cancer treatment, British Journal of Cancer, vol.74, issue.3, pp.327-365, 1996.
DOI : 10.1038/bjc.1996.362

G. Minotti, Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity, Pharmacological Reviews, vol.56, issue.2, pp.185-229, 2004.
DOI : 10.1124/pr.56.2.6

B. T. Mcgrogan, Taxanes, microtubules and chemoresistant breast cancer, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1785, issue.2, pp.1785-96, 2008.
DOI : 10.1016/j.bbcan.2007.10.004

H. Xiao, Insights into the mechanism of microtubule stabilization by Taxol, Proceedings of the National Academy of Sciences, vol.103, issue.27, pp.10166-73, 2006.
DOI : 10.1073/pnas.0603704103

S. V. Ambudkar, P-glycoprotein: from genomics to mechanism, Oncogene, vol.22, issue.47, pp.7468-85, 2003.
DOI : 10.1038/sj.onc.1206948

Y. Kimura, Mechanism of multidrug recognition by MDR1/ABCB1, Cancer Sci, vol.98, issue.9, pp.1303-1313, 2007.

M. J. Murphy, . Jr, and P. De-cremoux, Molecular Action and Clinical Relevance of Aromatase Inhibitors [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects], Oncologist Bull Cancer, vol.3, issue.6112, pp.129-130, 1998.

N. Ahmad and R. Kumar, Steroid hormone receptors in cancer development: A target for cancer therapeutics, Cancer Letters, vol.300, issue.1, pp.1-9, 2011.
DOI : 10.1016/j.canlet.2010.09.008

H. Rochefort, Canc??rogen??se hormonale chez la femme : des m??canismes ?? la pr??vention, Comptes Rendus Biologies, vol.331, issue.2, pp.104-117, 2008.
DOI : 10.1016/j.crvi.2006.07.009

J. Domont, [Neoadjuvant endocrine therapy for breast cancer: an overview] Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group The different roles of ER subtypes in cancer biology and therapy, Bull Cancer Lancet Nat Rev Cancer, vol.91, issue.118, pp.55-62, 1998.

R. J. Santen, History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target, Endocrine Reviews, vol.30, issue.4, pp.343-75, 2000.
DOI : 10.1210/er.2008-0016

D. E. Lake and C. Hudis, Aromatase inhibitors in breast cancer: an update, Cancer Control, issue.96, pp.490-498, 2002.

V. Tayal and B. S. Kalra, Cytokines and anti-cytokines as therapeutics ??? An update, European Journal of Pharmacology, vol.579, issue.1-3
DOI : 10.1016/j.ejphar.2007.10.049

K. Margolin, Cytokine therapy in cancer, Expert Opinion on Biological Therapy, vol.65, issue.10, pp.1495-505, 2008.
DOI : 10.1186/1479-5876-4-50

S. Brandau and H. Suttmann, Thirty years of BCG immunotherapy for nonmuscle invasive bladder cancer: a success story with room for improvement, Biomed Pharmacother, issue.6, pp.61-299, 2007.

J. F. Aldrich, Vaccines and immunotherapeutics for the treatment of malignant disease Immunotherapy of cancer, Clin Dev Immunol Eur J Pharmacol, vol.625, pp.6971581-6971584, 2009.

H. Cheng and T. Force, Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis, pp.114-134, 2010.
DOI : 10.1016/j.pcad.2010.06.006

R. S. Samant and L. A. Shevde, Recent Advances in Anti-Angiogenic Therapy of Cancer, Oncotarget, vol.2, issue.3, pp.122-156, 2011.
DOI : 10.18632/oncotarget.234

K. J. Gotink and H. M. Verheul, Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis Tumor angiogenesis: therapeutic implications, Folkman, J. N Engl J Med, vol.13, issue.7821, pp.1-14, 1971.

P. Giraud and J. M. Cosset, [Radiation toxicity to the heart: physiopathology and clinical data]. Bull Cancer, pp.147-53, 2004.

A. Mege, [Radiation-related heart toxicity Myocardial infarction risk and tamoxifen therapy for breast cancer, Cancer Radiother, pp.92-1614, 2005.

K. Pistevou-gompaki, Evaluation of cardiotoxicity five years after 2D planned, non-simulated, radiation therapy for left breast cancer. Ther Clin Risk Manag Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer, Oncologist, vol.83, issue.4612, pp.1359-62, 2008.

D. A. Patt, Cardiac Morbidity of Adjuvant Radiotherapy for Breast Cancer, Journal of Clinical Oncology, vol.23, issue.30, pp.7475-82, 2005.
DOI : 10.1200/JCO.2005.13.755

J. D. Floyd, Cardiotoxicity of cancer therapy Pathology of radiation and anthracycline cardiotoxicity, J Clin Oncol Pediatr Blood Cancer, vol.23, issue.877, pp.7685-96, 2005.

D. Bovelli, G. Plataniotis, and F. Roila, Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines, Annals of Oncology, vol.21, issue.Supplement 5, pp.277-82, 2010.
DOI : 10.1093/annonc/mdq200

J. Doyen, P. Giraud, and Y. Belkacemi, [Normal tissue tolerance to external beam radiation therapy: cardiac structures], Cancer Radiother, vol.14, pp.4-5, 2010.

B. Dietz, K. G. Van, and . Hem, Late-onset cardiotoxicity of chemotherapy and radiotherapy Deliargyris, Cardiotoxicity of cancer therapy, Neth J Med Cancer Invest, issue.66, pp.61-228, 1999.

E. Raschi, Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy, Pharmacology & Therapeutics, vol.125, issue.2, pp.196-218, 2010.
DOI : 10.1016/j.pharmthera.2009.10.002

J. J. Monsuez, Cardiac side-effects of cancer chemotherapy, International Journal of Cardiology, vol.144, issue.1, pp.3-15, 2010.
DOI : 10.1016/j.ijcard.2010.03.003

K. A. Wouters, Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies, British Journal of Haematology, vol.30, issue.1, pp.561-78, 2005.
DOI : 10.1016/S0140-6736(04)16626-9

R. L. Jones, C. Swanton, M. S. Ewer, and A. Cardiotoxicity, Anthracycline cardiotoxicity, Expert Opinion on Drug Safety, vol.17, issue.6, pp.791-809, 2006.
DOI : 10.1200/JCO.2006.06.1382

A. J. Birtle, Anthracyclines and cardiotoxicity, Clin Oncol (R Coll Radiol), vol.12, issue.3, pp.146-52, 2000.
DOI : 10.1007/s001740070057

S. Delemasure, Pr??vention de??la??cardiotoxicit?? des??anthracyclines??: approche fondamentale des??m??canismes mis en??jeu??; relations avec??les??donn??es cliniques, Annales de Cardiologie et d'Ang??iologie, vol.55, issue.2, pp.104-116, 2006.
DOI : 10.1016/j.ancard.2006.02.005

D. L. Hershman and A. I. Neugut, Anthracycline Cardiotoxicity: One Size Does Not Fit All!, JNCI Journal of the National Cancer Institute, vol.100, issue.15, pp.1046-1053, 2008.
DOI : 10.1093/jnci/djn241

E. T. Yeh and C. L. Bickford, Cardiovascular Complications of Cancer Therapy, Journal of the American College of Cardiology, vol.53, issue.24, pp.53-2231, 2009.
DOI : 10.1016/j.jacc.2009.02.050

T. Simunek, Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron, Pharmacol Rep, issue.1, pp.61-154, 2009.

D. B. Sawyer, Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis, pp.105-118, 2010.

V. I. Franco, Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines, Cardiology Research and Practice, vol.78, issue.2, p.134679, 2011.
DOI : 10.1200/JCO.2007.14.1242

J. M. Appel, Anthracycline-induced chronic cardiotoxicity and heart failure, Acta Oncologica, vol.44, issue.2, pp.576-80, 2007.
DOI : 10.1016/j.healun.2004.12.108

Y. L. Lyu, Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane, Cancer Res, issue.18, pp.67-8839, 2007.

R. D. Olson, Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol., Proceedings of the National Academy of Sciences, vol.85, issue.10, pp.85-3585, 1988.
DOI : 10.1073/pnas.85.10.3585

B. Bakouboula, R??versibilit?? d'un ??tat de choc cardiog??nique sous 5-fluorouracil, Annales de Cardiologie et d'Ang??iologie, vol.54, issue.4, pp.216-225, 2005.
DOI : 10.1016/j.ancard.2004.11.014

P. Tsibiribi, Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease, Bull Cancer, vol.93, issue.3, pp.27-30, 2006.

T. Stewart, N. Pavlakis, and M. Ward, Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina, Internal Medicine Journal, vol.13, issue.4, pp.303-310, 2010.
DOI : 10.1111/j.1445-5994.2009.02144.x

P. Saintigny, [Cardiovascular toxicity of some cancer agents (others than anthracyclines, fluoropyrimidines and trastuzumab)]. Bull Cancer, pp.174-84, 2004.

E. Salvatorelli, Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies, Journal of Pharmacology and Experimental Therapeutics, vol.318, issue.1, pp.318-424, 2006.
DOI : 10.1124/jpet.106.103846

G. Minotti, Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium, Clin Cancer Res, vol.7, issue.6, pp.1511-1516, 2001.

R. K. Hernandez, Tamoxifen Treatment in Danish Breast Cancer Patients and 5-Year Risk of Arterial Atherosclerotic Events: A Null Association, Cancer Epidemiology Biomarkers & Prevention, vol.17, issue.9, pp.2509-2520, 2008.
DOI : 10.1158/1055-9965.EPI-08-0570

B. Fisher, Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study, J Natl Cancer Inst, issue.22, pp.97-1652, 2005.

B. R. Bird and S. M. Swain, Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems, Clinical Cancer Research, vol.14, issue.1, pp.14-24, 2008.
DOI : 10.1158/1078-0432.CCR-07-1033

D. J. Grainger and P. M. Schofield, Tamoxifen for the prevention of myocardial infarction in humans: preclinical and early clinical evidence, Circulation, pp.112-3018, 2005.

B. Nordenskjold, Coronary Heart Disease Mortality After 5 Years of Adjuvant Tamoxifen Therapy: Results from a Randomized Trial, JNCI Journal of the National Cancer Institute, vol.97, issue.21, pp.97-1609, 2005.
DOI : 10.1093/jnci/dji342

J. P. Costantino, Coronary Heart Disease Mortality and Adjuvant Tamoxifen Therapy, JNCI Journal of the National Cancer Institute, vol.89, issue.11, pp.776-82, 1997.
DOI : 10.1093/jnci/89.11.776

M. Cushman, Tamoxifen and Cardiac Risk Factors in Healthy Women : Suggestion of an Anti-inflammatory Effect, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.21, issue.2, pp.255-61, 2001.
DOI : 10.1161/01.ATV.21.2.255

M. S. Elisaf, Tamoxifen-induced severe hypertriglyceridemia and pancreatitis, Ann Oncol, issue.118, pp.1067-1076, 2000.

M. S. Ewer and S. Gluck, A woman's heart, Cancer, vol.23, issue.9, pp.1813-1839, 2009.
DOI : 10.1002/cncr.24219

J. K. Williams, Tamoxifen Inhibits Arterial Accumulation of LDL Degradation Products and Progression of Coronary Artery Atherosclerosis in Monkeys, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.17, issue.2, pp.403-411, 1997.
DOI : 10.1161/01.ATV.17.2.403

A. M. Geiger, Stroke Risk and Tamoxifen Therapy for Breast Cancer, JNCI Journal of the National Cancer Institute, vol.96, issue.20, pp.96-1528, 2004.
DOI : 10.1093/jnci/djh285

K. Towns, P. L. Bedard, and S. Verma, Matters of the Heart: Cardiac Toxicity of Adjuvant Systemic Therapy for Early Stage Breast Cancer, Current Oncology, vol.15, issue.S1, pp.15-16, 2008.
DOI : 10.3747/co.2008.173

A. Howell and J. Cuzick, Vascular effects of aromatase inhibitors: Data from clinical trials, The Journal of Steroid Biochemistry and Molecular Biology, vol.95, issue.1-5, pp.1-5, 2005.
DOI : 10.1016/j.jsbmb.2005.04.005

E. Bria, Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues, Expert Opinion on Biological Therapy, vol.17, issue.12, pp.1963-71, 2008.
DOI : 10.1200/JCO.2007.13.5467

M. Campone, E. Bourbouloux, and P. Fumoleau, [Cardiac dysfunction induced by trastuzumab], Bull Cancer, vol.91, pp.166-73, 2004.

H. R. Mellor, Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer, Toxicological Sciences, vol.120, issue.1, pp.14-32, 2011.
DOI : 10.1093/toxsci/kfq378

H. L. Mcarthur and S. Chia, Cardiotoxicity of Trastuzumab in Clinical Practice, New England Journal of Medicine, vol.357, issue.1, pp.94-99, 2007.
DOI : 10.1056/NEJMc070065

T. Force, D. S. Krause, and R. A. Van-etten, Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition, Nature Reviews Cancer, vol.115, issue.5, pp.332-376, 2007.
DOI : 10.1038/nrc2106

A. Zambelli, Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues, The Breast, vol.20, issue.2, pp.176-83, 2011.
DOI : 10.1016/j.breast.2010.11.002

M. Guglin, R. Cutro, and J. D. Mishkin, Trastuzumab-Induced Cardiomyopathy, Journal of Cardiac Failure, vol.14, issue.5, pp.437-481, 2008.
DOI : 10.1016/j.cardfail.2008.02.002

E. T. Yeh, Cardiotoxicity Induced by Chemotherapy and Antibody Therapy, Annual Review of Medicine, vol.57, issue.1, pp.485-98, 2006.
DOI : 10.1146/annurev.med.57.121304.131240

M. Sonnenblick and A. Rosin, Cardiotoxicity of Interferon*, Chest, vol.99, issue.3, pp.557-61, 1991.
DOI : 10.1378/chest.99.3.557

T. F. Chu, Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib, The Lancet, vol.370, issue.9604, pp.2011-2020, 2007.
DOI : 10.1016/S0140-6736(07)61865-0

G. S. Orphanos, G. N. Ioannidis, and A. G. , Ardavanis, Cardiotoxicity induced by tyrosine kinase inhibitors, Acta Oncol, issue.7, pp.48-964, 2009.

C. Migdal and M. Serres, [Reactive oxygen species and oxidative stress, Med Sci, vol.27, issue.4, pp.405-417, 2011.

P. Menna, E. Salvatorelli, and G. Minotti, Anthracycline Degradation in Cardiomyocytes: A Journey to Oxidative Survival, Chemical Research in Toxicology, vol.23, issue.1, pp.6-10, 2010.
DOI : 10.1021/tx9003424

A. V. Kuznetsov, Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1813, issue.6, pp.1813-1144, 2011.
DOI : 10.1016/j.bbamcr.2011.03.002

URL : https://hal.archives-ouvertes.fr/inserm-00633082

Y. Zhao, Nox2 NADPH Oxidase Promotes Pathologic Cardiac Remodeling Associated with Doxorubicin Chemotherapy, Cancer Research, vol.70, issue.22, pp.9287-97, 2010.
DOI : 10.1158/0008-5472.CAN-10-2664

P. Menna, E. Salvatorelli, and G. Minotti, Doxorubicin Degradation in Cardiomyocytes, Journal of Pharmacology and Experimental Therapeutics, vol.322, issue.1, pp.408-427, 2007.
DOI : 10.1124/jpet.107.122820

B. Liu, Nitric Oxide Synthase Expressions in ADR-induced Cardiomyopathy in Rats, BMB Reports, vol.39, issue.6, pp.759-65, 2006.
DOI : 10.5483/BMBRep.2006.39.6.759

J. H. Doroshow, G. Y. Locker, and C. E. Myers, Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites, Journal of Clinical Investigation, vol.65, issue.1, pp.128-163, 1980.
DOI : 10.1172/JCI109642

M. Crohns, Local and systemic oxidant/antioxidant status before and during lung cancer radiotherapy, Free Radical Research, vol.238, issue.7, pp.43-646, 2009.
DOI : 10.1016/S0891-5849(99)00201-4

S. S. Khanzode, Antioxidant Enzymes and Lipid Peroxidation in Different Stages of Breast Cancer, Free Radical Research, vol.10, issue.1, pp.81-86, 2004.
DOI : 10.1080/01411590310001637066

R. Kizek, Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances, Pharmacology & Therapeutics, vol.133, issue.1
DOI : 10.1016/j.pharmthera.2011.07.006

Z. Junjing, Z. Yan, and Z. Baolu, Scavenging Effects of Dexrazoxane on Free Radicals, Journal of Clinical Biochemistry and Nutrition, vol.47, issue.3, pp.47-238, 2010.
DOI : 10.3164/jcbn.10-64

S. M. Swain, Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer., Journal of Clinical Oncology, vol.15, issue.4, pp.1318-1350, 1997.
DOI : 10.1200/JCO.1997.15.4.1318

T. Yan, Topoisomerase II??-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin, Molecular Cancer Therapeutics, vol.8, issue.5, pp.1075-85, 2009.
DOI : 10.1158/1535-7163.MCT-09-0139

S. E. Lipshultz, The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia, New England Journal of Medicine, vol.351, issue.2, pp.145-53, 2004.
DOI : 10.1056/NEJMoa035153

S. E. Lipshultz, Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial, The Lancet Oncology, vol.11, issue.10, pp.11-950, 2010.
DOI : 10.1016/S1470-2045(10)70204-7

H. S. Choi, Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors, Journal of Korean Medical Science, vol.25, issue.9, pp.1336-1378, 2010.
DOI : 10.3346/jkms.2010.25.9.1336

M. L. Hensley, American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants, Journal of Clinical Oncology, vol.27, issue.1, pp.127-172, 2009.
DOI : 10.1200/JCO.2008.17.2627

V. Santini, Amifostine: chemotherapeutic and radiotherapeutic protective effects, Expert Opinion on Pharmacotherapy, vol.154, issue.2, pp.479-89, 2001.
DOI : 10.1097/00008390-199804000-00011

T. Li, Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats, Cardiovascular Research, vol.46, issue.3, pp.523-553, 2000.
DOI : 10.1016/S0008-6363(00)00039-0

T. Li and P. K. Singal, Adriamycin-Induced Early Changes in Myocardial Antioxidant Enzymes and Their Modulation by Probucol, Circulation, vol.102, issue.17, pp.2105-2115, 2000.
DOI : 10.1161/01.CIR.102.17.2105

N. Siveski-iliskovic, Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect, Circulation, vol.91, issue.1, pp.10-15, 1995.
DOI : 10.1161/01.CIR.91.1.10

E. S. Park, Protective effects of N-acetylcysteine and selenium against doxorubicin toxicity in rats, J Vet Sci, issue.42, pp.129-165, 2003.

J. H. Doroshow, Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine., Journal of Clinical Investigation, vol.68, issue.4, pp.1053-64, 1981.
DOI : 10.1172/JCI110328

P. J. Oliveira, Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity, Toxicology and Applied Pharmacology, vol.200, issue.2, pp.159-68, 2004.
DOI : 10.1016/j.taap.2004.04.005

URL : http://hdl.handle.net/10316/5379

W. Arozal, Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats, Toxicology, vol.274, issue.1-3, pp.18-26
DOI : 10.1016/j.tox.2010.05.003

P. Spallarossa, Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro, Journal of Molecular and Cellular Cardiology, vol.37, issue.4, pp.837-883, 2004.
DOI : 10.1016/j.yjmcc.2004.05.024

V. Machado, Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin), Rev Port Cardiol, issue.10, pp.27-1277, 2008.

M. A. Ibrahim, Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity, Pharmacological Research, vol.60, issue.5, pp.60-373, 2009.
DOI : 10.1016/j.phrs.2009.05.007

M. Iqbal, Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats, Pharmacol Rep, vol.60, issue.3, pp.382-90, 2008.

C. Cadeddu, Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment, American Heart Journal, vol.160, issue.3, pp.487-488, 2010.
DOI : 10.1016/j.ahj.2010.05.037

J. L. Quiles, Antioxidant nutrients and adriamycin toxicity, Toxicology, vol.180, issue.1, pp.79-95, 2002.
DOI : 10.1016/S0300-483X(02)00383-9

S. Ghibu, Antioxidant Properties of an Endogenous Thiol: Alpha-lipoic Acid, Useful in the Prevention of Cardiovascular Diseases, Journal of Cardiovascular Pharmacology, vol.54, issue.5, pp.391-399, 2009.
DOI : 10.1097/FJC.0b013e3181be7554

S. Ghibu, Un dithiol endog??ne aux propri??t??s antioxydantes??: l???acide alpha-lipo??que, utilisation potentielle dans les pathologies cardiovasculaires, Annales de Cardiologie et d'Ang??iologie, vol.57, issue.3, pp.161-166, 2008.
DOI : 10.1016/j.ancard.2008.02.018

S. Granados-principal, New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients, Food and Chemical Toxicology, vol.48, issue.6, pp.1425-1463
DOI : 10.1016/j.fct.2010.04.007

K. A. Conklin, Cancer chemotherapy and antioxidants, J Nutr, vol.134, issue.11, pp.3201-3204, 2004.

K. Shimpo, Ascorbic acid and adriamycin toxicity, Am J Clin Nutr, vol.54, issue.6, pp.1298-1301, 1991.

S. Kalender, Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats, Brazilian Journal of Medical and Biological Research, vol.35, issue.11, pp.35-1379, 2002.
DOI : 10.1590/S0100-879X2002001100017

A. A. Al-majed, ALPHA-LIPOIC ACID AMELIORATES MYOCARDIAL TOXICITY INDUCED BY DOXORUBICIN, Pharmacological Research, vol.46, issue.6, pp.499-503, 2002.
DOI : 10.1016/S1043661802002311

R. M. Delgado, Cyclooxygenase-2 Inhibitor Treatment Improves Left Ventricular Function and Mortality in a Murine Model of Doxorubicin-Induced Heart Failure, Circulation, vol.109, issue.11, pp.1428-1461, 2004.
DOI : 10.1161/01.CIR.0000121354.34067.48

J. H. Silber, Enalapril to Prevent Cardiac Function Decline in Long-Term Survivors of Pediatric Cancer Exposed to Anthracyclines, Journal of Clinical Oncology, vol.22, issue.5, pp.820-828, 2004.
DOI : 10.1200/JCO.2004.06.022

D. Cardinale, Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition, Circulation, vol.114, issue.23, pp.114-2474, 2006.
DOI : 10.1161/CIRCULATIONAHA.106.635144

S. E. Lipshultz, Long-Term Enalapril Therapy for Left Ventricular Dysfunction in Doxorubicin-Treated Survivors of Childhood Cancer, Journal of Clinical Oncology, vol.20, issue.23, pp.20-4517, 2002.
DOI : 10.1200/JCO.2002.12.102

G. J. Yoon, Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?, J Am Coll Cardiol, issue.20, pp.56-1644, 2010.

D. Urbanova, Heart transplant in a childhood leukemia survivor: a case report, Exp Clin Transplant, vol.8, issue.1, pp.79-81

A. Hiona, Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of??mitochondrial function, The Journal of Thoracic and Cardiovascular Surgery, vol.142, issue.2, pp.396-403, 2011.
DOI : 10.1016/j.jtcvs.2010.07.097

L. W. Seymour, Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin, Journal of Clinical Oncology, vol.20, issue.6, pp.1668-76, 2002.
DOI : 10.1200/JCO.2002.20.6.1668

S. R. Roffler, J. Chan, and M. Y. Yeh, Potentiation of radioimmunotherapy by inhibition of topoisomerase I, Cancer Res, vol.54, issue.5, pp.1276-85, 1994.

C. J. Lin, The Prognostic Value of Atrial Fibrillation on 30-Day Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention, International Heart Journal, vol.52, issue.3, pp.153-161
DOI : 10.1536/ihj.52.153

O. D. Pedersen, Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction, European Heart Journal, vol.27, issue.3, pp.290-295, 2006.
DOI : 10.1093/eurheartj/ehi629

A. Dziewierz, Prognostic significance of new onset atrial fibrillation in acute coronary syndrome patients treated conservatively, Cardiol J, vol.17, issue.1, pp.57-64

M. Ohsawa, Mortality Risk Attributable to Atrial Fibrillation in Middle-Aged and Elderly People in the Japanese General Population, Circulation Journal, vol.71, issue.6, pp.71-814, 2007.
DOI : 10.1253/circj.71.814

W. A. Wattigney, G. A. Mensah, and J. B. Croft, Increased Atrial Fibrillation Mortality: United States, 1980-1998, American Journal of Epidemiology, vol.155, issue.9, pp.819-845, 2002.
DOI : 10.1093/aje/155.9.819